1.
Gastroenterology
; 160(3): 925-928.e4, 2021 02.
Article
in English
| MEDLINE | ID: covidwho-977281
Subject(s)
Angiotensin-Converting Enzyme 2/metabolism , COVID-19/enzymology , Crohn Disease/enzymology , Gastrointestinal Microbiome , Ileum/enzymology , Inflammation Mediators/metabolism , Receptors, Virus/metabolism , SARS-CoV-2/enzymology , Angiotensin-Converting Enzyme 2/genetics , Animals , COVID-19/virology , Case-Control Studies , Colitis, Ulcerative/enzymology , Colitis, Ulcerative/immunology , Colitis, Ulcerative/microbiology , Crohn Disease/genetics , Crohn Disease/immunology , Crohn Disease/microbiology , Disease Models, Animal , Down-Regulation , Host-Pathogen Interactions , Humans , Ileum/immunology , Ileum/microbiology , Mice, Knockout , SARS-CoV-2/pathogenicity , STAT Transcription Factors/genetics , STAT Transcription Factors/metabolism , Serine Endopeptidases/metabolism , Signal Transduction , Toll-Like Receptors/genetics , Toll-Like Receptors/metabolism
2.
Nat Commun
; 11(1): 3774, 2020 07 24.
Article
in English
| MEDLINE | ID: covidwho-672188
ABSTRACT
Immune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated with inhibitors of inflammatory cytokines. These cytokines are involved in the pathogenesis of coronavirus disease 2019 (COVID-19). Investigating anti-SARS-CoV-2 antibody responses in IMIDs we observe a reduced incidence of SARS-CoV-2 seroconversion in IMID patients treated with cytokine inhibitors compared to patients receiving no such inhibitors and two healthy control populations, despite similar social exposure. Hence, cytokine inhibitors seem to at least partially protect from SARS-CoV-2 infection.